CRIM1, the Antagonist of BMPs, is a Potential Risk Factor of Cancer

被引:11
|
作者
Zeng, Hui [1 ]
Tang, Liling [1 ]
机构
[1] Chongqing Univ, Coll Bioengn, Key Lab Biorheol Sci & Technol, Minist Educ, Chongqing 400044, Peoples R China
关键词
Antagonist; angiogenesis; BMPs; cancer treatment targets; CRIM1; EMT; BONE MORPHOGENETIC PROTEINS; DEFECTS; EXPRESSION; REVEALS; DOMAINS;
D O I
10.2174/1568009614666140725094125
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cysteine-rich motor neuron1 protein (CRIM1), a novel antagonist of bone morphogenetic proteins (BMPs), is reported to regulate the processing of BMPs preprotein into mature protein and the delivery of BMPs to the cell surface. Previous studies have shown that CRIM1 is an important player in regulating placental development, organogenesis, angiogenesis and kidney disease. Here, we propose that CRIM1 is a potential risk factor in cancer progression and metastasis. The epithelial-mesenchymal transition (EMT), which is characterized by the loss of epithelial phenotype and the acquisition of mesenchymal characteristics, is closely associated with invasion and metastasis of tumors. At the same time, it is hard for us to ignore the importance of angiogenesis in the genesis and progression of cancer. In this review we summarized the construction and previous researches of CRIM1. Furthermore, as it may be involved in tumor development and progression through its potential role in the EMT, capillary formation and angiogenesis maintenance, we proposed for the first time that CRIM1 may be a cancer related factor.
引用
收藏
页码:652 / 658
页数:7
相关论文
共 50 条
  • [41] The transcription factor FOXQ1 in cancer
    Koch, Stefan
    CANCER AND METASTASIS REVIEWS, 2025, 44 (01)
  • [42] Functional STR within PTPN11: a novel potential risk factor for colorectal cancer
    Wang, Huiping
    Wang, Wen
    Xue, Yuanzhi
    Aweya, Jude Juventus
    Yang, Xue
    Zhu, Zhansheng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (12): : 11710 - 11716
  • [43] Associations between hypoxia-inducible factor-1α (HIF-1α) gene polymorphisms and risk of developing breast cancer
    Naidu, R.
    Har, Y. C.
    Taib, N. A.
    NEOPLASMA, 2009, 56 (05) : 441 - 447
  • [44] Fetal Constraint as a Potential Risk Factor for Craniosynostosis
    Sanchez-Lara, Pedro A.
    Carmichael, Suzan L.
    Graham, John M., Jr.
    Lammer, Edward J.
    Shaw, Gary M.
    Ma, Chen
    Rasmussen, Sonja A.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2010, 152A (02) : 394 - 400
  • [45] Insulin-like growth factor-1 and childhood cancer risk
    Badr, Mohamed
    Hassan, Tamer
    El Tarhony, Shereen
    Metwally, Wael
    ONCOLOGY LETTERS, 2010, 1 (06) : 1055 - 1059
  • [46] Potential signaling pathway of hypoxia-inducible factor in lung cancer and its gene polymorphism with lung cancer risk
    Liao, Shou-He
    Liu, Wen-Zhou
    Liu, Tao
    Sun, Yu
    Feng, Xu
    Zhou, Hua-Fu
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2015, 35 (04) : 233 - 237
  • [47] Cytoplasmic HAX1 Is an Independent Risk Factor for Breast Cancer Metastasis
    Trebinska-Stryjewska, Alicja
    Szafron, Lukasz
    Rembiszewska, Alina
    Wakula, Maciej
    Tabor, Sylwia
    Sienkiewicz, Renata
    Owczarek, Joanna
    Balcerak, Anna
    Felisiak-Golabek, Anna
    Grzybowska, Ewa A.
    JOURNAL OF ONCOLOGY, 2019, 2019
  • [48] Gender is a risk factor for lung cancer
    Gasperino, James
    MEDICAL HYPOTHESES, 2011, 76 (03) : 328 - 331
  • [49] Behavioral Effects of a Potential Novel TAAR1 Antagonist
    Lam, Vincent M.
    Mielnik, Catharine A.
    Baimel, Corey
    Beerepoot, Pieter
    Espinoza, Stefano
    Sukhanov, Ilya
    Horsfall, Wendy
    Gainetdinov, Raul R.
    Borgland, Stephanie L.
    Ramsey, Amy J.
    Salahpour, Ali
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [50] Gremlin1: a BMP antagonist with therapeutic potential in Oncology
    Jin, Zhao
    Cao, Yanshuo
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (06) : 716 - 727